Genetic susceptibility to tobacco carcinogenesis

Cancer Investigation

Volumn 17, Issue 8, 1999, Pages 645-659

  Spitz, Margaret R ^b   Wei, Qingyi ^b   Li, Guojun ^b   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BENZO[A]PYRENE; BLEOMYCIN; CYTOCHROME P450; DEBRISOQUINE 4 HYDROXYLASE; DIMETHYLNITROSAMINE DEMETHYLASE; GLUTATHIONE TRANSFERASE;

CANCER RISK; CANCER SUSCEPTIBILITY; CHEMICAL CARCINOGENESIS; DNA ADDUCT; DNA REPAIR; DRUG CARCINOGENICITY; ENZYME POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOBACCO;

EID: 0032746203     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909032849     Document Type: Review

References (139)

1. Parnell RW: Smoking and cancer [letter]. Lancet 1:963, 1951.
2. Shopland DR, Eyre HJ, Pechacek TF: Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 83:1142-1148, 1991.
3. Amos CI: Identifying gene-environment interactions in cancer etiology. Cancer Bull 46:214-219, 1994.
4. Tokuhata GK, Lilienfeld AM: Familial aggregation of lung cancer in humans. J Natl Cancer Inst 30:289-312, 1963.
5. Ooi WL, Elston RC, Chen VW, et al: Increased familial risk for lung cancer. J Natl Cancer Inst 76:217-222, 1986.
6. Sellers TA, Elston RC, Rothschild H: Familial risk of cancer among randomly selected cancer probands. Genet Epidemiol 5: 381-392, 1988.
7. Sellers TA, Bailey-Wilson JE, Elston RC, et al: Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst 82:1272-1279, 1990.
8. Yang P, Schwartz AG: Genetic epidemiology of lung cancer. II. Control segregation analysis of families of non-smoking lung cancer probands. Genet Epidemiol 10:344, 1993.
9. Carmelli D, Swan GE, Robinerre D, et al: Genetic influence on smoking-a study of male twins. N Engl J Med 327:829-833, 1992.
10. Amos CI, Caporaso NE, Weston A: Host factors in lung cancer risk: a review of interdisciplinary studies. Cancer Epidemiol Biomarkers Prev 1:505-513, 1992.
11. Bishop JM: Molecular themes in oncogenesis. Cell 64:235-248, 1991.
12. Levine AJ: The tumor suppressor genes. Annu Rev Biochem 62: 623-651, 1993.
13. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996.
14. Farber E: The multistep nature of cancer. Cancer Res 44:4217-4223, 1984.
15. Hoeijmakers JHJ: Human nucleotide excision repair syndromes. Molecular clues to unexpected intricacies. Eur J Cancer 30: 1912-1921, 1994.
16. Hagmar L, Brogger A, Hansteen IL, et al: Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 54:2919-2922, 1994.
17. Bonassi S, Abbondandolo A, Camurri L, et al: Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet Cytogenet 79:133-135, 1995.
18. Hsu TC, Johnston DA, Cherry LM, et al: Sensitivity to genotoxic events of bleomycin in humans: possible relationship to environmental carcinogens. Int J Cancer 43:403-409, 1989.
19. Spitz MR, Hsu TC, Wu X, et al: Mutagen sensitivity as a biologic marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 4:99-103, 1995.
20. Wu X, Delclos, GL, Annegers, FJ, et al: A case-control study of wood-dust exposure, mutagen sensitivity, and lung-cancer risk. Cancer Epidemiol Biomarkers Prev 4:583-588, 1995.
21. Strom SS, Wu XF, Sigurdson AJ, et al: Lung cancer, smoking patterns and mutagen sensitivity in Mexican-Americans. J Natl Cancer Inst Monogr 18:29-33, 1995.
22. Spitz MR, Fueger JJ, Beddingfield NA, et al: Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res 49: 4626-4628, 1989.
23. Phillips DH: Fifty years of B[a]P. Nature 303:468-472, 1983.
24. Gelboin HV: Benzo[a]pyrene metabolism, activation, and carcinogenesis. Role and regulation of mixed function oxidases and related enzymes. Physiol Rev 60:1107-1166, 1980.
25. MacLeod MC, Tang MS: Interaction of benzo[a]pyrene-diol-epoxides with linear and supercoiled DNA. Cancer Res 45:51-56, 1985.
26. Jernstrom B, Graslund A: Covalent binding of benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide to DNA. Molecular structure, induced mutations and biological consequences. Biophys Chem 49:185-199, 1994.
27. Cosman M, de los Santos C, Fiala R, et al: Solution conformation of the major adducts between the carcinogen (+)-anti-benzo[a]-pyrene diol epoxide and DNA. Proc Natl Acad Sci USA 89: 1914-1918, 1992.
28. Wei Q, Gu J, Cheng L, et al: Benzo[a]pyrene diol epoxide induced chromosomal aberrations in normal human lymphocytes. Cancer Res 56:3975-3979, 1996.
29. Wu X, Gu J, Amos CI, et al: A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung cancer cases and controls. Cancer 83:1118-1127, 1998.
30. Wei Q, Spitz MR, Gu J, et al: DNA repair capacity correlates with mutagen sensitivity in lymphoblastoid cell lines. Cancer Epidemiol Biomarkers Prev 5:199-204, 1996.
31. Wu X, Hsu TC, Annegers JF, et al: A case-control study of non-random distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer patients. Cancer Res 5:557-561,1995.
32. Wu X, Zhao Y, Kemp BL, et al: Chromosome 5 aberrations and genetic predisposition to lung cancer. Int J Cancer 79:490-493, 1998.
33. Roche J, Boldog F, Robinson M, et al: Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12:1289-1297, 1996.
34. Killary AM, Wolf ME, Giambemardi TA, et al: Definition of a tumor suppressor locu within human chromosome 3p21-p22. Proc Natl Acad Sci USA 89:10877-10881, 1992.
35. Sozzi G, Sard L, De Gregorio L, et al: Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57:2121-2123, 1997.
36. Wu X, Zhao Y, Honn SE, et al: Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res 90:358-363, 1998.
37. Kellerman G, Luyten-Kellerman M, Shaw CR: Genetic variation of arylhydrocarbon hydroxylase in human lymphocytes. Am J Hum Genet 25:327-331, 1973.
38. Kouri RE, McKinney CE, Slomiany DJ, et al: Positive correlation between high aryl hydrocarbon hydroxylase activity in primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 42:5030-5037, 1982.
39. Anttila S, Hirvonen A, Husgavel-Pursiainen K, et al: Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on hisiological type of lung cancer. Carcinogenesis 15:1133-1135, 1994.
40. Paigen B, Ward E, Steenland K, et al: Arylhydrocarbon hydroxylase in cultured lymphocytes of twins. Am J Hum Genet 30:561-571, 1978.
41. Bartsch H, Petruzzelli S, De Flora S, et al: Carcinogen metabolism in human lung tissues and the effect of tobacco smoking. Results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 98:119-124, 1992.
42. Bartsch H, Hietanen E, Petruzzelli S, et al: Possible prognostic value of pulmonary AH-locus-linked enzymes in patients with tobacco-related lung cancer. Int J Cancer 46:185-188, 1990.
43. Nakachi K, Imai K, Hayashi S, et al: Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 51:5177-5180, 1991.
44. Jaiswal AK, Gonzalez FJ, Nebert DW: Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo(a)pyrene metabolism. Nucleic Acids Res 13:4503-4520, 1985.
45. Kawajiri K, Nakachi K, Imai K, et al: Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 263:131-133, 1990.
46. Hayashi S, Watanabe J, Nakachi K, et al: Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 110:407-411, 1991.
47. Cosma G, Crofts F, Taioli E, et al: Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 40:309-316, 1993.
48. Crofts F, Cosma GN, Currie D, et al: A novel CYP11 gene polymorphism in African-Americans. Carcinogenesis 14:1729-1731, 1993.
49. Kelsey K, Wiencke JK, Spitz MR: A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans. Carcinogenesis 5:1121-1124, 1994.
50. London SJ, Daly AK, Fairbrother KS, et al: Lung cancer risk in African Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Res 55:6035-6037, 1995.
51. Shields PG, Caporaso NE, Falk RT, et al: Lung cancer, race, and CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 2:481-485, 1993.
52. Hirvonen A, Husgafvel Pursiainen K, Anttila S, et al: Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 2:259-263, 1992.
53. Tefre T, Ryberg D, Haugen A, et al: Human CYP1A1 (cytochrome P(1)450) gene. Lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1:20-25, 1991.
54. Garcia-Closas M, Kelsey KT, Wiencke JK, et al: A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility. Cancer Causes Control 8:544-553, 1997.
55. Xu X, Kelsey KT, Wiencke JK, et al: Cytochrome P4501A1 Msp1 polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5:687-692, 1996.
56. Nakachi K, Imai K, Hayashi S, et al: Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53:2994-2999, 1993.
57. Crofts F, Taioli E, Trachman J, et al: Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15:2961-2963, 1994.
58. Cosma G, Crofts F, Currie D, et al: Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of the human CYP1A1 gene. Cancer Epidemiol Biomarkers Prev 2:53-57, 1993.
59. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, et al: Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene. Lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1:485-489, 1992.
60. Mooney LA, Bell DA, Santella RM, et al: Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 18:503-509, 1997.
61. Ayesh R, Idle SR, Ritchie JC, et al: Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312: 169-170, 1984.
62. Crespi CL, Penman BW, Gelboin HV, et al: A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 12:1197-1201, 1991.
63. Heim M, Meyer UA: Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-532, 1990.
64. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, et al: PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 3:19-27, 1993.
65. Wolf CR, Smith CAD, Gough AC, et al: Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13:1035-1038, 1992.
66. Shaw GL, Falk RT, Deslauriers J, et al: Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 4:41-48, 1995.
67. Law MR, Hetzel MR, Idle JR: Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 59:686-687, 1989.
68. Caporaso NE, Shields PG, Landi MT, et al: The debrisoquine metabolic phenotype and DNA-based assays, implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect 98: 101-105, 1992.
69. Bouchardy C, Benhamou S, Dayer P: The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 56: 251-253, 1996.
70. Benhamou S, Bouchardy C, Paoletti C, et al: Effects of CYP2D6 activity and tobacco on larynx cancer risk. Cancer Epidemiol Biomarkers Prev 5:683-686, 1996.
71. Cholerton S, Arpanahi A, McCracken N, et al: Poor metabolizers of nicotine and CYP2D6 polymorphism. Lancet 343:62-63, 1994.
72. Guengerich FP, Kim DH, Iwasaki M: Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179, 1991.
73. Koop DR: Oxidative and reductive metabolism by cytochrome P4502E1. FASEB J 6:724-730, 1992.
74. Yamazaki H, Inui Y, Yun C, et al: Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13:1789-1794, 1992.
75. Uematsu F, Ikawa S, Kikuchi H, et al: Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer, possible relevance to low smoking exposure. Pharmacogenetics 4:58-63, 1994.
76. Kato S, Shields PG, Caporaso NE, et al: Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol Biomarkers Prev 3:515-518, 1994.
77. Hayashi SI, Watanabe J, Kawajiri K: Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIEI gene. J Biochem 111:559-565, 1991.
78. Watanabe J, Yang JP, Eguchi H, et al: An Rsa I polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population. Jpn J Cancer Res 86:245-248, 1995.
79. Sugimura H, Hamada GS, Suzuki I, et al: CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil. Pharmacogenetics 5:S145-148, 1995.
80. Stephens EA, Taylor JA, Kaplan N, et al: Ethnic variation in the CYP2E1 gene: Polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 4: 185-195, 1994.
81. Ingelman-Sundberg M, Johansson I, Persson I, et al: Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 2: 264-271, 1992.
82. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, et al: The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 14:85-88, 1993.
83. Persson I, Johansson I, Bergung H, et al: Genetic polymorphism of cytochrome P4502E1 in a Swedish population: Relationship to incidence of lung cancer. FEBS Lett 319:207-211, 1993.
84. Wu X, Shi H, Jiang H, et al: Association between chromosome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 18:967-973, 1997.
85. Seree EM, Villard PH, Re JL, et al: High inducibility of mouse renal CYP2E1 gene by tobacco smoke and its possible effect on DNA single strand breaks. Biochem Biophys Res Commun 219: 429-434, 1996.
86. Ketterer B, Harris JM, Talaska G et al: The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 98:87-94, 1992.
87. Seidegard J, Guthenberg C, Pero RW, et al: The trans-stilbene oxide-active glutathione transferase in human mononuclear leucocytes is identical with the hepatic glutathione transferase mu. Biochem J 246:783-785, 1987.
88. Seidegard J, Vorachek WR, Pero RW, et al: Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85:7293-7297, 1988.
89. Brockmoller J, Gross D, Kerb R, et al: Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reaction. Biochem Pharmacol 43: 647-650, 1992.
90. Seidegard J, Pero RW, Markowitz MM, et al: Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis 11:33-36, 1990.
91. Zhong S, Howie AF, Ketterer B, et al: Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 12: 1533-1537, 1991.
92. Kihara M, Noda K. Okamoto N: Increased risk of lung cancer in Japanese smokers with class mu glutathione S-transferase gene deficiency. Cancer Lett 71:151-155, 1993.
93. Nazar-Stewart V, Motulsky AG, Eaton DL, et al: The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 53:2313-2318, 1993.
94. Heckbert SR, Weiss NS, Hornung SK, et al: Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst 84:414-422, 1992.
95. Brockmoller J, Kerb R, Drakoulis N, et al: Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res 53:1004-1011, 1993.
96. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, et al: The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 14:1479-1481, 1993.
97. Kihara M, Noda K: Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis 15:415-418, 1994.
98. Hayashi S, Watanabe J, Kawajiri K: High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 83:866-870, 1992.
99. London SJ, Daly AK, Cooper J, et al: Polymorphism of glutathione s-transferase m1 and lung cancer risk among African-Americans and Caucasians in Los Angeles county, California. J Natl Cancer Inst 87:1246-1253, 1995.
100. Garcia-Closas M, Kelsey KT, Wiencke JK, et al: Nutrient intake as a modifier of the association between lung cancer and glutathione-S-transferase mu deletion. Proc Am Assoc Cancer Res 36: A1675, 1995.
101. McWilliams JE, Sanderson BJ, Harris EL, et al: Glutathione S-transferase MI (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 4:589-594, 1991.
102. Meyer DJ, Coles B, Pemble SE, et al: Theta, a new class of glutathione transferases purified from rat and man. Biochem J 274:409-414, 1991.
103. Pemble S, Schroeder KR, Spencer SR, et al: Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300:271-276, 1994.
104. el-Zein R, Conforti-Froes N, Au WW: Interactions between genetic predisposition and environmental toxicants for development of lung cancer. Environ Mol Mutagen 30:196-204, 1997.
105. Kelsey KT, Spitz MR, Zuo ZF, et al: Polymorphisms in the glutathione S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States). Cancer Causes Control 8:554-559, 1997.
106. Jourenkova N, Reinikainen M, Benhamou S, et al: Lung cancer risk in relation to glutathione S-transferase (GSTM1 and GSTT1) genotypes and tobacco exposure. Proc Am Assoc Cancer Res 38:A1433, 1997.
107. Saarikoski ST, Voho A, Reinikainen M, et al: Combined effects of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 77:516-521, 1998.
108. Alexandrie AK, Sundberg MI, Seidegard J, et al: Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 15:1785-1790, 1994.
109. Blum M, Demierre A, Grant DM, et al: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 88: 5237-5241, 1991.
110. Deguchi T: Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 267: 18140-18147, 1992.
111. Bell DA, Taylor JA, Butler MA, et al: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acelylator allele common in African-Americans. Carcinogenesis 14:1689-1692, 1993.
112. Vineis P, Bartsch H, Caporaso N, et al: Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369:154-156, 1994.
113. Wu X, Liu JH, Trizna Z, et al: The association of N-acetylator, mutagen sensitivity and lung cancer risk. Proc Am Assoc Cancer Res 37:263, 1996.
114. Knowles MA, Shaw ME, Proctor AJ: Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 8:1357-1364, 1993.
115. Kadlubar FF, Badawi AF: Genetic susceptibility and carcinogenDNA adduct formation in human urinary bladder carcinogenesis. Toxicol Lett 82-83:s627-s632, 1995.
116. Bell DA, Badawi AF, Lang NP, et al: Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: Association of NAT110 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 55:5226-5229, 1995.
117. Wu X, Hsu TC, Cao S, et al: Deletion in poly(ADP-ribose)polymerase pseudogene and lung cancer risk. Carcinogenesis 19:93-98, 1998.
118. Cleaver JE, Kraemer K: Xeroderma pigmentosum. In: The Metabolic Basis of Inherited Diseases II, edited by CR Scriver, AL Beaudet, WS Sly, D Valle, New York, McGraw-Hill, 1989, pp. 2949-2971.
119. Friedberg EC: DNA Repair, New York, WH Freedman and Company, 1985.
120. Tang MS, Pierce JR, Doisy RP, et al; Differences and similarities in the repair of two benzo[a]pyrene diol epoxide isomers induced DNA adducts by uvrA, uvrB, and uvrC gene products. Biochemistry 31:8429-8436, 1992.
121. Sancer A: Mechanisms of DNA excision repair. Science 266: 1954-1956, 1994.
122. Athas WF, Hedayati M, Matanoski GM, et al: Development and field-test validation of an assay for DNA repair in circulating human lymphocytes. Cancer Res 51:5786-5793, 1991.
123. Wei Q, Matanoski OM, Farmer ER, et al: DNA repair and susceptibility to skin cancer. Am J Epidemiol 140:589-607, 1994.
124. Wei Q, Matanoski GM, Farmer ER, et al: DNA repair related to multiple skin cancers and drug use. Cancer Res 54:437-440, 1994.
125. Wei Q, Cheng L, Hong WK, et al: Reduced DNA repair capacity in lung cancer patients. Cancer Res 56:4103-4107, 1996.
126. Li D, Wang M, Cheng L, et al: In vitro induction of benzo[a]pyrene diol epoxide-induced DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. Cancer Res 56:3638-3641, 1996.
127. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 7:1543-1551, 1986.
128. Watson WP: Postradiolabeling for detection of DNA damage. Mutagenesis 2:319-331, 1987.
129. Phillips DH, Hewer A, Grover PL: Aromatic DNA adducts in human bone marrow and peripheral blood leukocytes. Carcinogenesis 7:2071-2075, 1986.
130. Phillips DH, Hewer A, Martin CN, et al: Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 336: 790-792, 1988.
131. 32P-postlabeling test for covalent DNA binding of chemicals in vivo: application to a variety of aromatic carcinogenes and methylating agents. Carcinogenesis 5:231-243, 1984.
132. van Schooten FJ, Hillebrand, MJ, van Leeuwen FE, et al: Polycyclic aromatic hydrocarbon-DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels in the lung. Carcinogenesis 13:987-993, 1992.
133. 32P-post-labelling assay. Carcinogenesis 1:503-508, 1991.
134. Gupta RC, Earley K, Sharma S: Use of human peripheral blood lymphocytes to measure DNA binding capacity of chemical carcinogens. Proc Natl Acad Sci USA 85:3513-3517, 1988.
135. Everson RB, Randerath E, Santella RM, et al: Detection of smoking-related covalent DNA adducts in human placenta. Science 231:54-59, 1986.
136. 32P-post-labelling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and ex-smokers. Carcinogenesis 12:1301-1305, 1991.
137. Barret JM, Calsou P, Salles B: Deficient nucleotide excision repair activity in protein extracts from normal human lymphocytes. Carcinogenesis 7:1611-1616, 1995.
138. Krolewski B, Little JB, Reynolds RJ: Effect of duration of exposure to benzo[a]pyrene diol-epoxide on neoplastic transformation, mutagenesis, cytotoxicity and total covalent binding to DNA of rodent cells. Teratog Carcinog Mutagen 8:127-136, 1988.
139. Wei Q, Spitz ME. The role of DNA repair capacity in susceptibility to lung cancer. Cancer Metastasis Rev 16:295-307, 1997.